# US 2023/0056702 A1 · Reducing oxygen levels in the gastrointestinal tract

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0056702 A1
- Document ID: US20230056702A1
- Status: Published application
- Kind: A1
- Application number: 17/821,644
- Filed: 2022-08-23
- Published: 2023-02-23
- Earliest claimed: 2021-08-23
- Assignees: Northeastern University
- Applicants: Northeastern University
- Inventors: Kim LEWIS; Norman PITT; Madeleine MORRISSETTE
- Web page: https://patentgrep.com/patent/US20230056702A1

## CPC

- A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00)
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 35/34: Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes (vascular smooth muscle A61K35/44)
- A61K 35/68: Protozoa, e.g. flagella, amoebas, sporozoans, plasmodium or toxoplasma
- A61K 36/05: Chlorophycota or chlorophyta (green algae), e.g. Chlorella
- A61K 36/062: Ascomycota
- A61K 36/064: Saccharomycetales, e.g. baker's yeast
- A61K 36/21: Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
- A61K 36/81: Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present disclosure is directed towards a method of treating a disease or condition associated with gut inflammation. The present disclosure comprises administering, to a patient in need thereof, a composition comprising oxygen-scavenging membrane fragments or membrane vesicles. In some embodiments, membrane vesicles are derived from bacteria. In some embodiments, membrane vesicles are derived from the cytoplasmic membranes of Escherichia coli, Salmonella typhimurium, Gluconobacter oxydans, Pseudomonas aeruginosa, or Acetobacter.

## Claims

### Claim 1

A method of treating a disease or condition associated with gut inflammation comprising administering, to a patient in need thereof, a therapeutically effective amount of a composition comprising oxygen-scavenging membrane fragments and/or membrane vesicles, or a pharmaceutically acceptable salt, solvate, hydrate, cocrystal, or prodrug thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the oxygen-scavenging membrane fragments and/or membrane vesicles are derived from bacteria.

### Claim 3 (depends on 1)

The method of claim 1, wherein the oxygen-scavenging membrane fragments and/or membrane vesicles are derived from cytoplasmic membranes of Escherichia coli, Salmonella typhimurium, Gluconobacter oxydans, Pseudomonas aeruginosa, or Acetobacter.

### Claim 4 (depends on 1)

The method of claim 1, wherein sources of the oxygen-scavenging membranes are beef heart muscle, potato tuber, spinach, Saccharomyces, Neurospora, Aspergillus, Euglena, or Chlamydomonas.

### Claim 5 (depends on 1)

The method of claim 1, wherein the composition contains the oxygen-scavenging membrane fragments in the amount of about 0.001 units/mL to about 100 units/mL, from about 0.01 units/mL to about 10 units/mL, from about 0.3 unit/mL to about 10 units/mL, or from about 1 unit/mL to about 10 units/mL.

### Claim 6 (depends on 1)

The method of claim 1, wherein the composition is administered as a parabiotic to prevent inflammatory bowel disease development.

### Claim 7 (depends on 1)

The method of claim 1, wherein the composition is taken to maintain microbiome diversity.

### Claim 8 (depends on 1)

The method of claim 1, wherein the composition is OXYRASE.

### Claim 9 (depends on 1)

The method of claim 1, wherein the disease or condition is inflammatory bowel disease, traveler's diarrhea, Crohn's disease, ulcerative colitis, celiac disease, polyps, cancer, celiac disease, diverticulitis, malabsorption, short bowel syndrome, gastritis, gastroparesis, gastroenteritis, peptic ulcers, or intestinal ischemia.

### Claim 10 (depends on 1)

The method of claim 1, wherein the composition contains a cryoprotectant in an amount of about 15% by weight to about 65% by weight, or from about 50 wt % to about 65 wt %.

### Claim 11 (depends on 10)

The method of claim 10, wherein the cryoprotectant is s glycerol, dimethyl sulfoxide (DMSO), and glycols, including ethylene glycol, propylene glycol, polyethylene glycol, or glycerol.

### Claim 12 (depends on 1)

The method of claim 1, wherein the composition further comprises a hydrogen donating substance in the amount of about 0.1 wt % to about 5 wt %.

### Claim 13 (depends on 12)

The method of claim 12, wherein the oxygen-scavenging membrane fragments and/or membrane vesicles are derived from mitochondria that reduce oxygen to water in the presence of the hydrogen donating substance.

### Claim 14 (depends on 12)

The method of claim 12, wherein the donating substance is lactic acid, succinic acid, alpha-glycerol phosphate, formic acid, malic acid, pyruvic acid or the corresponding salts thereof.

### Claim 15 (depends on 1)

The method of claim 1, wherein the composition may be in the form of an injection, a solution, a suspension, or emulsion.

### Claim 16 (depends on 1)

The method of claim 1, wherein the composition is taken orally.

### Claim 17 (depends on 1)

The method of claim 1, wherein the composition is administered through a rectal route.

### Claim 18 (depends on 1)

The method of claim 1, wherein the composition is administered intracolonically.
